SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.

Fiche publication

Date publication

mai 2020

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre , Pr MERLIN Jean-Louis , Dr GILSON Pauline

Tous les auteurs :
Dardare J, Witz A, Merlin JL, Gilson P, Harlé A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32429474

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a five-year survival of less than 5%. Incidence of PDAC is constantly increasing and is predicted to become the second leading cause of cancer in Western countries within a decade. Despite research and therapeutic development, current knowledge about PDAC molecular mechanisms still needs improvements and it seems crucial to identify novel therapeutic targets. Genomic analyses of PDAC revealed that transforming growth factor β (TGFβ) signaling pathways are modified and the gene is altered in 47% and 60% of cases, respectively, highlighting their major roles in PDAC development. TGFβ can play a dual role in malignancy depending on the context, sometimes as an inhibitor and sometimes as an inducer of tumor progression. TGFβ signaling was identified as a potent inducer of epithelial-to-mesenchymal transition (EMT), a process that confers migratory and invasive properties to epithelial cells during cancer. Therefore, aberrant TGFβ signaling and EMT are linked to promoting PDAC aggressiveness. TGFβ and SMAD pathways were extensively studied but the mechanisms leading to cancer promotion and development still remain unclear. This review aims to describe the complex role of SMAD4 in the TGFβ pathway in patients with PDAC.